[go: up one dir, main page]

MX2018001173A - Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa. - Google Patents

Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa.

Info

Publication number
MX2018001173A
MX2018001173A MX2018001173A MX2018001173A MX2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A
Authority
MX
Mexico
Prior art keywords
modulators
compounds useful
tnf alpha
cyclic compounds
compounds
Prior art date
Application number
MX2018001173A
Other languages
English (en)
Inventor
Xiao Hai-Yun
Jiang Bin
Duan Jingwu
T G Dhar Murali
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2018001173A publication Critical patent/MX2018001173A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I) (ver Fórmula) o una sal del mismo, en donde: el anillo A es un anillo carbocíclico o heterocíclico de 3 a 6 elementos; X es CR1 o N; Y es - (CR5R5)m-; Z es - (CR5R5)n-; y q, R1, R2, R3, R4, R6, R7, R8, R9, y R10. También se describen métodos para usar tales compuestos como moduladores del TNFa, y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles en el tratamiento de enfermedades inflamatorias y autoinmunes.
MX2018001173A 2015-08-03 2016-08-02 Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa. MX2018001173A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200415P 2015-08-03 2015-08-03
PCT/US2016/045104 WO2017023902A1 (en) 2015-08-03 2016-08-02 Cyclic compounds useful as modulators of tnf alpha

Publications (1)

Publication Number Publication Date
MX2018001173A true MX2018001173A (es) 2018-04-24

Family

ID=56610045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001173A MX2018001173A (es) 2015-08-03 2016-08-02 Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa.

Country Status (13)

Country Link
US (1) US10335392B2 (es)
EP (1) EP3331889B1 (es)
JP (1) JP6811233B2 (es)
KR (1) KR102679517B1 (es)
CN (1) CN108137609B (es)
AU (1) AU2016301215A1 (es)
BR (1) BR112018001980A2 (es)
CA (1) CA2994703A1 (es)
EA (1) EA201890421A1 (es)
ES (1) ES2828696T3 (es)
IL (1) IL257159A (es)
MX (1) MX2018001173A (es)
WO (1) WO2017023902A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168641A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Tricyclic modulators of tnf signaling
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2021226269A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
MX2022013657A (es) 2020-05-05 2023-02-01 Nuvalent Inc Quimioterápicos de éter macrocíclico heteroaromático.
EP4408844A1 (en) 2021-10-01 2024-08-07 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
KR20250051688A (ko) * 2022-08-08 2025-04-17 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 TGF-β 억제제 화합물 및 그 사용

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5149386A (ja) * 1974-10-28 1976-04-28 Hitachi Ltd Shuchukanshiseigyohoho
DE69814049T2 (de) 1997-02-25 2004-02-19 The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
JPH11228539A (ja) * 1997-12-03 1999-08-24 Taisho Pharmaceut Co Ltd 含窒素四環性化合物
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
CN1633434A (zh) 2002-01-31 2005-06-29 第一制药株式会社 咪唑并[1,2－a]吡啶衍生物
AU2003298839A1 (en) 2002-12-03 2004-06-23 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
WO2009045174A1 (en) 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CA2756137C (en) 2009-03-23 2015-11-24 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
KR101669334B1 (ko) * 2013-09-30 2016-10-25 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
JP6483697B2 (ja) 2013-12-09 2019-03-13 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性のモジュレーターとしての縮合二環式ヘテロ芳香族誘導体
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9920052B2 (en) 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2980464T3 (es) 2014-10-06 2024-10-01 Signal Pharm Llc Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos
WO2016149439A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf
JP6793658B2 (ja) 2015-03-18 2020-12-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物
US10189840B2 (en) 2015-03-18 2019-01-29 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds

Also Published As

Publication number Publication date
CN108137609B (zh) 2021-07-16
EP3331889A1 (en) 2018-06-13
JP6811233B2 (ja) 2021-01-13
KR102679517B1 (ko) 2024-06-27
EP3331889B1 (en) 2020-09-23
US10335392B2 (en) 2019-07-02
KR20180031773A (ko) 2018-03-28
US20180221344A1 (en) 2018-08-09
ES2828696T3 (es) 2021-05-27
JP2018525377A (ja) 2018-09-06
BR112018001980A2 (pt) 2018-09-18
EA201890421A1 (ru) 2018-07-31
CN108137609A (zh) 2018-06-08
IL257159A (en) 2018-03-29
WO2017023902A1 (en) 2017-02-09
AU2016301215A1 (en) 2018-03-22
CA2994703A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
MX2018001173A (es) Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa.
HK1252623A1 (zh) 可用作TNFα调节剂的杂环化合物
UA122498C2 (uk) Біциклічні похідні, спосіб їх отримання та фармацевтичні композиції, що їх містять
MX2017011433A (es) Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf).
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
PH12017502266A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201790024A1 (ru) Модуляторы toll-подобных рецепторов для лечения вич
UA118680C2 (uk) Похідні заміщеного гліоксамідом піроламіду та їхнє застосування як лікарських препаратів для лікування гепатиту в
MY190243A (en) Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MD4779B1 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX2021003792A (es) Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
MX2017011577A (es) Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
MX378435B (es) Administración específica del sitio de un inhibidor de btk.
GEP20196942B (en) Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors
MX374728B (es) MODULADORES DE ROR GAMMA (RORy).
EA201692480A1 (ru) Фармацевтическая композиция
MX377329B (es) Moduladores de ror gamma (ror?).
MX383592B (es) Moduladores de ror gamma (ror?).
MX2017011434A (es) Compuestos heterociclicos triciclicos sustituidos.
TW201613864A (en) Novel compounds
MD20170011A2 (ro) Compuşi imidazopiridazinici
MX378111B (es) Moduladores de ror gamma (ror?).
MX381129B (es) Inhibidores de dopamina-b-hidroxilasa.
IN2014DN09314A (es)